CD39 is expressed by a wide range of cutaneous T-cell lymphomas.
Fiche publication
Date publication
avril 2024
Journal
Skin health and disease
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BENSUSSAN Armand
Tous les auteurs :
Battesti G, Thonnart N, Bozonnat A, Ram-Wolff C, de Masson A, Bensussan A, Bagot M, Marie-Cardine A, Battistella M
Lien Pubmed
Résumé
CD39, an ectoenzyme in the immunosuppressive CD39/CD73/adenosine pathway, known to promote solid tumour outgrowth and spreading, was investigated in both skin and blood compartments of cutaneous T cell lymphomas. CD39 was overexpressed by peripheral blood T-cells in Sezary syndrome and mycosis fungoides, and in skin-infiltrating lymphocytes of Sezary syndrome, mycosis fungoides, subcutaneous panniculitis-like T-cell lymphoma and primary cutaneous CD30-positive lymphoproliferation. Our study emphasizes the interest in using CD39/CD73/adenosine pathway blocking agents for cutaneous T cell lymphomas treatment.
Référence
Skin Health Dis. 2024 04;4(2):e334